


**REMARKS**

Attached hereto is a marked-up version of the changes made to the specification by the present amendment. The attached page is captioned "Version With Marking To Show Changes Made."

Should the Examiner believe that a discussion with Applicants' representative would further the prosecution of this application, the Examiner is respectfully invited to contact the undersigned.

Please address all correspondence to Thomas Hoxie, Novartis Corporation, Patent and Trademark Department, 564 Morris Avenue, Summit, NJ 07901. The commissioner is hereby authorized to charge any other fees with may be required under 37 CFR §1.16 and 1.17, or credit any overpayment, to Deposit Account No. 19-0134.

Respectfully submitted,



Robert J. Gorman, Jr.  
Reg. No. 41,789  
(678) 415.4389

Novartis Corporation  
Patent and Trademark Department  
564 Morris Avenue  
Summit, NJ 07901

s:\jc legal department\public\patents\prosecut\31174\al\preliminary amendment.doc



Application No. 09/428,278

**VERSION WITH MARKING TO SHOW CHANGES MADE**

***In the Specification***

The following paragraph has been inserted to page 1, line 4, immediately following the Title, but before the Field of the Invention:

This application claims priority to provisional application Serial No. 60/325,779, which was converted to a provisional application by petition from non-provisional application Serial No. 09/428,067, filed October 27, 1999.

RECEIVED  
AUG 13 2002  
TECHNOLOGY CENTER 1700

COPY OF PAPERS  
ORIGINALLY FILED